Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$4.35
$1.10
$43.35
$2.55M1.83103,866 shs137,800 shs
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$5.73
$3.07
$6.24
$155.11M2.39158,476 shs66,708 shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.13
+1.2%
$6.77
$5.01
$17.81
$1.15B2.696.28 million shs1.11 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.80
+2.4%
$0.86
$0.52
$5.17
$67.82M1.641.13 million shs36,841 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.05
+0.5%
$3.16
$1.60
$10.48
$117.67M1.35795,914 shs42,675 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00%0.00%0.00%0.00%0.00%
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
Novavax, Inc. stock logo
NVAX
Novavax
+6.51%+6.51%-5.50%+4.30%-41.63%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
+5.90%+15.37%-7.49%+24.94%-74.19%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
+8.21%+8.21%-9.28%-24.25%+44.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
4.4917 of 5 stars
3.12.00.04.71.30.83.1
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.2006 of 5 stars
3.11.00.04.70.61.70.0
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
1.6741 of 5 stars
3.61.00.00.01.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00
N/AN/AN/A
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
0.00
N/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00138.60% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.25
Hold$6.11661.43% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50573.23% Upside

Current Analyst Ratings Breakdown

Latest NVAX, STRO, EIGR, LJPC, and TARA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/16/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$2.00
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$15.77M0.00N/AN/A$37.68 per share0.00
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$75.72M0.00N/A7.95($2.94) per share0.00
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.69N/AN/A($3.89) per share-1.83
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$62.04M1.09N/AN/A$0.54 per share1.49
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$4.77 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/A
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/A
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.6989.060.0638.14%-115.51%29.99%8/14/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)

Latest NVAX, STRO, EIGR, LJPC, and TARA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.43N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/A
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/A
3.31
3.24
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
N/A
4.02
3.52
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
2.16
2.16
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
18.03
18.03

Institutional Ownership

CompanyInstitutional Ownership
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
62.46%
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
97.06%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
561.48 million1.42 millionOptionable
La Jolla Pharmaceutical stock logo
LJPC
La Jolla Pharmaceutical
6124.94 million15.89 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million79.48 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million33.76 millionOptionable

Recent News About These Companies

Protara Therapeutics, Inc. (TARA) - Yahoo Finance
Analysts Set Expectations for TARA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eiger BioPharmaceuticals stock logo

Eiger BioPharmaceuticals NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

La Jolla Pharmaceutical stock logo

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.12 +0.09 (+1.21%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.80 +0.02 (+2.36%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.04 +0.02 (+0.50%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.